Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C

Autor: Jérôme, Guéchot, Candice, Trocmé, Jean-Charles, Renversez, Nathalie, Sturm, Jean-Pierre, Zarski, E-S, Zafrani
Přispěvatelé: CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire [Grenoble] (CHU), Institut Albert Bonniot - Ontogénèse et oncogénèse moléculaires, CHU Grenoble-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département d'hépato-gastroentérologie, CHU Grenoble-Université Grenoble Alpes (UGA), ANRS HC EP 23 Fibrostar Study Group
Rok vydání: 2011
Předmět:
Liver Cirrhosis
Male
Pathology
Cirrhosis
Clinical Biochemistry
Chronic liver disease
Gastroenterology
Cohort Studies
0302 clinical medicine
Fibrosis
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Prospective Studies
Prospective cohort study
MESH: Cohort Studies
liver fibrosis
MESH: Aged
MESH: Middle Aged
medicine.diagnostic_test
General Medicine
Hepatitis C
Middle Aged
3. Good health
MESH: Hepatitis C
Chronic
MESH: Reproducibility of Results
ELF test
MESH: Young Adult
030220 oncology & carcinogenesis
Liver biopsy
blood marker
030211 gastroenterology & hepatology
diagnostic accuracy
Female
MESH: Liver Cirrhosis
Adult
medicine.medical_specialty
Adolescent
Sciences du Vivant [q-bio]/Médecine humaine et pathologie
03 medical and health sciences
Young Adult
Internal medicine
medicine
Humans
[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry
Molecular Biology/Biochemistry [q-bio.BM]
Aged
MESH: Adolescent
MESH: Humans
Receiver operating characteristic
business.industry
Biochemistry (medical)
MESH: Biological Markers
Reproducibility of Results
MESH: Adult
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
MESH: ROC Curve
Hepatitis C
Chronic
medicine.disease
Confidence interval
MESH: Male
MESH: Prospective Studies
ROC Curve
hepatitis C
business
MESH: Female
Biomarkers
Zdroj: Clinical Chemistry and Laboratory Medicine
Clinical Chemistry and Laboratory Medicine, De Gruyter, 2012, 50 (4), pp.693-699. ⟨10.1515/cclm-2011-0858⟩
Clinical Chemistry and Laboratory Medicine, 2012, 50 (4), pp.693-699. ⟨10.1515/cclm-2011-0858⟩
ISSN: 1437-4331
1434-6621
DOI: 10.1515/cclm-2011-0858⟩
Popis: The Enhanced Liver Fibrosis (ELF) score combining serum hyaluronan, N-terminal peptide of type III procollagen and tissue inhibitor of metalloproteinase-1, was reported as relevant in predicting liver fibrosis in chronic liver disease and proposed as an alternative to liver biopsy.: We evaluated the ELF score in a cohort of chronic hepatitis C (CHC) patients included in a multicenter prospective study (ANRS HC EP 23 Fibrostar) using commercial reagents, different from those developed by the manufacturer of the Siemens ELF™ test.: In 512 CHC, the ELF score, using ROC curves, showed good predictive performances for severe fibrosis [AUROC=0.82; 95% confidence interval (CI) 0.78–0.86]and for cirrhosis (AUROC=0.85; 95% CI 0.81–0.90), but slightly lower for significant fibrosis (AUROC=0.78; 95% CI 0.74–0.82). The Obuchowski measure (0.81) showed that the ELF score globally performed as a marker of liver fibrosis. The ELF score predicted significant fibrosis (cut-off=9.0) with a sensitivity of 0.86, a specificity of 0.62, a positive predictive value (PPV) of 0.80 and a negative predictive value (NPV) of 0.70. For extensive fibrosis (cut-off=9.33), sensitivity was 0.90, specificity was 0.63, PPV was 0.73 and NPV was 0.85. For cirrhosis (cut-off=9.35), sensitivity was 0.83, specificity was 0.75, PPV was 0.44 and NPV was 0.95.: This study confirms the ELF score performance as an index to predict liver fibrosis or cirrhosis in CHC. The ELF test, using validated reagents, could be added to the health authorities approved non-invasive tests in assessing fibrosis as surrogate to liver biopsy.
Databáze: OpenAIRE
Externí odkaz: